Roche’s RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA)
Treating RA patients with severe, progressive disease in the first two years after diagnosis (early RA) could prevent damage to joints and stop the disease from progressing1,2 RoACTEMRA with and without MTX achieved greater inhibition of structural joint damage compared with MTX alone in the early RA population1 Basel, 8 September 2014 – Roche (SIX: […]